Notice: This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends LOGC vs. EDIT, SELB, QURE, VYGR, SGMO, HZO, CHUY, EXTO, SPTN, and MYTEShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include Editas Medicine (EDIT), Selecta Biosciences (SELB), uniQure (QURE), Voyager Therapeutics (VYGR), Sangamo Therapeutics (SGMO), MarineMax (HZO), Chuy's (CHUY), Almacenes Éxito (EXTO), SpartanNash (SPTN), and MYT Netherlands Parent B.V. (MYTE). LogicBio Therapeutics vs. Editas Medicine Selecta Biosciences uniQure Voyager Therapeutics Sangamo Therapeutics MarineMax Chuy's Almacenes Éxito SpartanNash MYT Netherlands Parent B.V. Editas Medicine (NASDAQ:EDIT) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Do analysts rate EDIT or LOGC? Editas Medicine presently has a consensus price target of $9.08, indicating a potential upside of 266.26%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 0 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.54LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in EDIT or LOGC? Editas Medicine received 220 more outperform votes than LogicBio Therapeutics when rated by MarketBeat users. However, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 53.81% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31153.81% Underperform Votes26746.19% LogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% Does the media prefer EDIT or LOGC? In the previous week, Editas Medicine had 3 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 0 mentions for LogicBio Therapeutics. Editas Medicine's average media sentiment score of 0.84 beat LogicBio Therapeutics' score of 0.00 indicating that Editas Medicine is being referred to more favorably in the media. Company Overall Sentiment Editas Medicine Positive LogicBio Therapeutics Neutral Is EDIT or LOGC more profitable? LogicBio Therapeutics has a net margin of -141.03% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% LogicBio Therapeutics -141.03%-81.98%-52.13% Which has better valuation and earnings, EDIT or LOGC? Editas Medicine has higher earnings, but lower revenue than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$78.12M2.62-$153.22M-$2.56-0.97LogicBio Therapeutics$287M0.64-$317M-$5.79-1.20 Do insiders and institutionals hold more shares of EDIT or LOGC? 71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 0.4% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, EDIT or LOGC? Editas Medicine has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. SummaryEditas Medicine beats LogicBio Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Wide Moat ResearchA huge crack is forming in the US economyFormer Trump Advisor Warning: “An Economic Rupture Is Coming” The legendary financier Brad Thomas served on Trump’s advisory board for years. Now he’s stepping forward with a terrifying new warning. “Even the rich aren’t safe,” he says. “I’m taking steps to protect my family.”Learn how to protect yourself too, click here. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$182.38M$4.63B$23.57B$8.84BDividend YieldN/A0.99%168.62%4.07%P/E Ratio-1.2012.96103.3414.75Price / Sales0.640.677.0388.44Price / CashN/A32.4719.9532.45Price / Book0.776.006.224.65Net Income-$317M$97.69M$676.59M$224.84M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics0.7071 of 5 stars$6.94+4.0%N/AN/A$182.38M$287M-1.2062EDITEditas Medicine4.7586 of 5 stars$2.48-1.6%$9.08+266.3%-74.6%$204.72M$78.12M-0.97230Short Interest ↓SELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Gap DownHigh Trading VolumeQUREuniQure3.2423 of 5 stars$5.82-5.8%$17.00+192.1%-15.5%$283.67M$15.84M-1.17500VYGRVoyager Therapeutics4.6644 of 5 stars$5.27-2.2%$17.00+222.6%-22.7%$287.90M$250.01M7.42100Analyst UpgradeAnalyst RevisionSGMOSangamo Therapeutics2.4519 of 5 stars$1.96+3.2%$7.00+257.1%+409.5%$408.95M$176.23M-2.61480Earnings ReportAnalyst RevisionHZOMarineMax4.7284 of 5 stars$29.58+0.6%$41.83+41.4%-2.5%$668.21M$2.43B17.934,050Short Interest ↓Positive NewsCHUYChuy's0.7491 of 5 stars$37.48flat$33.25-11.3%N/A$645.78M$460.07M24.507,400Analyst ForecastEXTOAlmacenes ÉxitoN/A$3.85-2.5%N/A-45.3%$624.59M$4.90B0.0043,134Gap DownSPTNSpartanNash4.4891 of 5 stars$18.22flat$20.00+9.8%-16.7%$615.11M$9.73B13.7017,000Positive NewsMYTEMYT Netherlands Parent B.V.0.8583 of 5 stars$6.32+3.6%$4.88-22.9%+158.0%$538.91M$909.70M-21.071,817News CoverageGap Up Related Companies and Tools Related Companies Editas Medicine Alternatives Selecta Biosciences Alternatives uniQure Alternatives Voyager Therapeutics Alternatives Sangamo Therapeutics Alternatives MarineMax Alternatives Chuy's Alternatives Almacenes Éxito Alternatives SpartanNash Alternatives MYT Netherlands Parent B.V. Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LOGC) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredThe Stock Powering Musk’s AI Revolution—RevealedImagine being able to invest in Tesla, PayPal, or SpaceX before the world knew their potential. Today, you ...InvestorPlace | SponsoredTrump’s EPIC Stock Market RallyPutting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU. In fact, according to ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LOGC Stock Alerts